Takeda Pharmaceutical Company Ltd (TAK) Options

TAK under. $16

TAK over $10

Just saying,

https://www.takeda.com/newsroom/newsreleases/2022/takedas-biologics-license-application-bla-for-dengue-vaccine-candidate-tak-003-granted-priority-review-by-us-food-and-drug-administration

4 months or less until an answer. Expedited review is six months or less now. It was accepted Nov 22nd.

Big if we get FDA apprvoval. ETF's in the know are sucking up shares.

Other approved drug has serious side effects vs. ours.

300M cases a year from mosquito bites.

Boing X 2

Takeda’s Pipeline Has Potential to Contribute Significantly to Revenue Growth Over Next Decade

https://www.businesswire.com/news/home/20201208005955/en/Takeda%E2%80%99s-Pipeline-Has-Potential-to-Contribute-Significantly-to-Revenue-Growth-Over-Next-Decade

Japan's Takeda eyes new focus on vaccines after OTC asset sales - CEO

https://www.reuters.com/article/health-coronavirus-takeda-vaccines-idUSKBN27M0F7

MIT-Takeda program launches

Research projects will harness the power of artificial intelligence to positively impact human health.

https://news.mit.edu/2020/mit-takeda-program-launches-research-ai-and-human-health-0618

Takeda shares tumbled as much as 9.3 percent in early trading in Tokyo on Wednesday. The Japanese company is offering the equivalent of 49 pounds ($68.55) per share, including 27.26 pounds in stock and 21.75 pounds in cash, Shire said in a statement. That’s a 60 percent premium to Shire’s closing share price on March 27, before Takeda disclosed it was interested in the US drug maker.

ADR is 3:1 - NICE!
60 percent upside
Added 36.83 US stock
Added 29.38 US cash


Not a bad deal!

So how does the Shire shareholder make out on this deal?

Takeda shares tumbled as much as 9.3 percent in early trading in Tokyo on Wednesday. The Japanese company is offering the equivalent of 49 pounds ($68.55) per share, including 27.26 pounds in stock and 21.75 pounds in cash, Shire said in a statement. That’s a 60 percent premium to Shire’s closing share price on March 27, before Takeda disclosed it was interested in the US drug maker.

Where is the 60percent premium to Close of March 27 2018 at shire 128.87

Takeda article: enGene Shines with a Host of Big Name Collaborations

http://marketexclusive.com/engene-shines-with-a-host-of-big-name-collaborations/1281/